Invention Grant
- Patent Title: Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
-
Application No.: US16309860Application Date: 2017-06-14
-
Publication No.: US11242408B2Publication Date: 2022-02-08
- Inventor: Ismail Ceylan , Gerry Quash , Mileidys Perez-Alea , Guillaume Martin
- Applicant: ADVANCED BIODESIGN , Jean-Yves Quash
- Applicant Address: FR Saint-Priest; FR Gometz la Ville
- Assignee: ADVANCED BIODESIGN,Jean-Yves Quash
- Current Assignee: ADVANCED BIODESIGN,Jean-Yves Quash
- Current Assignee Address: FR Saint-Priest; FR Gometz la Ville
- Agency: Troutman Pepper Hamilton Sanders LLP
- Priority: EP16305724 20160614
- International Application: PCT/EP2017/064553 WO 20170614
- International Announcement: WO2017/216227 WO 20171221
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/00 ; C07K16/44 ; G01N33/53 ; G01N33/68 ; G01N33/558
Abstract:
The present invention concerns an ex vivo method for the monitoring of apoptosis which is based on the detection of free gamma-glutamyl-L-epsilon-Lysine (GGEL) in a biological sample of a subject with a monoclonal antibody specific to GGEL. The invention also relates to the monoclonal antibody specific to GGEL, as well as to diagnostic kits containing such a ligand.
Public/Granted literature
- US20190169313A1 MONOCLONAL ANTIBODY SPECIFIC FOR GAMMA-GLUTAMYL-L-EPSILON-LYSINE FOR THE MONITORING OF APOPTOSIS Public/Granted day:2019-06-06
Information query
